Open AccessEffects of imidapril therapy on endogenous fibrinolysis in patients with recent myocardial infarction
Author(s) -
Soejima Hirofumi,
Ogawa Hisao,
Yasue Hirofumi,
Suefuji Hisakazu,
Kaikita Koichi,
Nishiyama Koichi
Publication year - 1997
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.4960200507
Subject(s) - medicine , fibrinolysis , plasminogen activator , placebo , myocardial infarction , ace inhibitor , plasminogen activator inhibitor 1 , tissue plasminogen activator , angiotensin converting enzyme , endocrinology , pharmacology , blood pressure , alternative medicine , pathology
Background : Treatment with an angiotensin‐con verting enzyme (ACE) inhibitor in patients with myocardial infarction has been shown to modify endogenous fibrinolysis. Hypothesis : We investigated the effects of the ACE inhibitor imidapril on endogenous fibrinolysis in association with the serum ACE activity. Methods : In a randomized, double‐blind, placebo‐controlled study beginning 4 weeks after uncomplicated myocardial infarction, 15 patients received imidapril (5 mg daily) (imidapril group) and another 15 received placebo therapy (placebo group) for 4 weeks. Blood sampling was performed before the start of administration and on Days 3, 7, and 28 after the start of administration. Serum ACE activity and plasma fibrinolytic variables [plasminogen activator inhibitor (PAI) activity, plasminogen activator inhibitor type 1 (PAI‐1) antigen level, and tissue type plasminogen activator (TPA) antigen level] were measured. Results : There was no difference between the imidapril and placebo groups in serum ACE activity or plasma fibrinolytic variables before administration. Serum ACE activity decreased significantly on Days 3, 7, and 28 in the imidapril group. The decrease of PAI activity and PAI‐1 antigen levels was significantly less on Days 7 and 28, but not on Day 3. The TPA antigen level in the imidapril group was unchanged. None of the parameters in the placebo group was changed. Conclusion : The ACE inhibitor imidapril modified fibrinolysis, but the effects occurred after the inhibition of serum ACE activity.